Informations générales (source: ClinicalTrials.gov)
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)
Interventional
Phase 1/Phase 2
Revolution Medicines, Inc. (Voir sur ClinicalTrials)
janvier 2024
décembre 2028
02 décembre 2025
The purpose of this platform study is to evaluate the safety, tolerability,
pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as
a monotherapy or combined with Standard(s) of Care (SOC) or with each other.
The first four subprotocols include the following:
Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C:
RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:07 | Contacter | |||
Critères
Tous
All Patients (unless otherwise noted):
- ≥ 18 years of age
- ECOG PS is 0 to 1
- Adequate organ function as outlined by the study
- Received prior standard therapy appropriate for tumor type and stage
- Must have pathologically documented, locally advanced or metastatic KRAS
G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol
A)
- Must have pathologically documented, locally advanced or metastatic RAS-mutated
NSCLC (Subprotocol B)
- Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated
NSCLC (Subprotocol C and Subprotocol D)
Exclusion criteria:
All Patients:
- Primary central nervous system (CNS) tumors
- Impaired gastrointestinal (GI) function that may significantly alter the absorption
of RMC drugs
- Major surgery < 28 days of first dose
- Active or history of interstitial lung disease (ILD) or pneumonitis requiring
steroids
Other inclusion/exclusion criteria may apply.